Elderly Patients with Locally Advanced NSCLC: No Survival Benefit from Postoperative Radiation Therapy

Share this content:

(ChemotherapyAdvisor) – Postoperative radiotherapy (PORT) is not associated with improved survival for elderly patients with completely resected, stage III non–small-cell lung cancer (NSCLC) with N2 lymph node involvement, according to results of a study published in Cancer online February 13.

Noting the potential role of PORT for this population remains controversial, the authors used the Surveillance, Epidemiology, and End Results (SEER) registry linked to Medicare records to compare survival of a concurrent cohort of 1,307 elderly patients 66 years of age or older who had N2 disease treated with and without PORT. Use of PORT in 710 patients (54%) was not associated with improved survival (HR=1.11) at 1 and 3 years.

“These findings have important clinical implications, because SEER data indicate that a large percentage of elderly patients currently receive PORT despite the lack of definitive evidence about its effectiveness. The potential effectiveness of PORT should be evaluated further in randomized controlled trials,” the authors wrote.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs